Drug-eluting stent thrombosis
Results from a pooled analysis including 10 randomized studies
Raúl Moreno, MD, FESC*,
Cristina Fernández, MD,
Rosana Hernández, MD, FESC,
Fernando Alfonso, MD, FESC,
Dominick J. Angiolillo, MD,
Manel Sabaté, MD, FESC,
Javier Escaned, MD, FESC,
Camino Bañuelos, MD, FESC,
Antonio Fernández-Ortiz, MD, FESC and
Carlos Macaya, MD, FESC
Division of Interventional Cardiology, Cardiovascular Institute, Hospital Clínico San Carlos, Madrid, Spain
View larger version (42K):
[in a new window]
|
Figure 1 (A) Comparison between the rate of stent thrombosis in patients allocated to drug-eluting stents (DES) or bare-metal stents (BMS) in the randomized studies and in the pooled population. (B) Comparison between the rate of late stent thrombosis in patients allocated to DES or BMS in the randomized studies and in the pooled population. CI = confidence interval; OR = odds ratio.
|
|
View larger version (25K):
[in a new window]
|
Figure 2 Relation between stent length and the rate of drug-eluting stent (DES) thrombosis in the different studies included in the meta-analysis. CI = confidence interval.
|
|
|
